Meeting
2019 ASCO Annual Meeting
Long-term survival of adjuvant high-dose (HDC) vs weekly cisplatin (WC) for human papilloma-virus (HPV) and non-HPV head and neck squamous cell carcinoma (HNSCC).
Authors
Katharine Andress Rowe Price
Mayo Clinic, Rochester, MN
Katharine Andress Rowe Price , Ashish V. Chintakuntlawar , Robert Leonard Foote , Yolanda I. Garces , Daniel Ma , Michelle A. Neben-Wittich , Eric J. Moore , Jan C. Kasperbauer , Daniel L. Price , Jeffrey R. Janus , Kathryn M. Van Abel , Jessica Lyn Geiger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Citation
J Clin Oncol 37, 2019 (suppl; abstr 6071)
DOI
10.1200/JCO.2019.37.15_suppl.6071
Abstract #
6071
Poster Bd #
60
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Discovery of a reliable and robust methylome classifier of HPV driven head and neck cancer with favorable response to chemoradiation: A multicenter study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
First Author: Bouchra Tawk
Poster
2015 ASCO Annual Meeting
Differential impact of cisplatin dose intensity on human papillomavirus (HPV)-related (+) and HPV-unrelated (−) locoregionally advanced head and neck squamous cell carcinoma (LAHNSCC).
First Author: Anna Spreafico
Poster
2023 ASCO Annual Meeting
Introduction of E-Score: A gene expression score to characterize immunogenic versus oncogenic HPV expression in HNSCC.
First Author: Bailey Fabiny Garb
Poster
2021 ASCO Annual Meeting
Outcomes and prediction of lethal recurrence after transoral robotic surgery for HPV+ head and neck cancer.
First Author: Devraj Basu